Segments (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Expenses

The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under U.S. GAAP to the Company’s total net loss in the statements of operations (in thousands).

	Three Months Ended
	2025		2024
Operating expenses:
Bexotegrast - clinical trial and third party contracting costs	21,589		17,217
Employee-related expenses - research and development (excluding stock-based compensation)	10,486		9,138
General and administrative costs (excluding stock-based compensation)	10,289		8,650
Other segment items	16,571		17,387
Segment loss	58,935		52,392
Reconciliation of segment loss
Interest and other (income) expense, net	(3,568)		(5,882)
Interest expense	799		445
Net loss	$	56,166	$	46,955